IR@PKUHSC  > 北京大学医药卫生分析中心
学科主题公共卫生
Peptide-based Radiopharmaceuticals for Targeted Tumor Therapy
Dong, C.1,2; Liu, Z.1,2; Wang, F.1,2
关键词Tumor Radiotracer Targeted Therapy Peptide Receptor Radionuclide Therapy
刊名CURRENT MEDICINAL CHEMISTRY
2014
21期:1页:139-152
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Biochemistry & Molecular Biology ; Chemistry, Medicinal ; Pharmacology & Pharmacy
研究领域[WOS]Biochemistry & Molecular Biology ; Pharmacology & Pharmacy
关键词[WOS]RECEPTOR RADIONUCLIDE THERAPY ; STIMULATING HORMONE PEPTIDE ; DISSEMINATED NEUROENDOCRINE TUMORS ; RADIOLABELED SOMATOSTATIN ANALOGS ; DUCTAL PANCREATIC ADENOCARCINOMA ; BETA-EMITTING RADIONUCLIDES ; IN-VIVO ; POSITIVE TUMORS ; PHASE-II ; MEDIATED RADIOTHERAPY
英文摘要

A series of radiolabeled peptides have been designed and optimized for tumor-targeted peptide receptor radionuclide therapy (PRRT). Pre-clinical and clinical applications of PRRT have shown promising results on tumor response, overall survival, and quality of life in patients with several kinds of tumors. Y-90-DOTA-TOC and Lu-177-DOTA-TATE are two of the most common radiopharmaceuticals with symptomatic improvements and complete clinical data. In addition to somatostatin analogs, radiolabeled peptides have been developed to target the relative receptors overexpressed in the tumors, such as integrin alpha(v)beta(3), gastrin-releasing peptide receptor (GRPR), melanocortin-1 receptor (MC1-R), cholecystokinin (CCK) receptor, and glucagon-like peptide-1 receptor (GLP-1R). Several strategies have been designed to improve the therapeutic efficacy of PRRT. For instance, radiolabeled peptides could be optimized by the amino acid modification and radionuclide selection. Healthy tissue protective agents and multi-cycle procedures could effectively decrease the side effects of PRRT. Furthermore, combination treatments, including PRRT combined with surgery, chemotherapeutic agents, or radiosensitizing agents could be applied to increase the effectiveness of PRRT. In this review, the current progress of peptide-based radiopharmaceuticals for tumor-targeted PRRT was summarized. Radiopharmaceuticals currently under clinical investigation were also described.

语种英语
WOS记录号WOS:000327778900010
项目编号81125011 ; 81222019 ; 30930030 ; 81000625 ; 812011 27 ; 2013CB733802 ; 2011CB707703 ; 2011YQ030114 ; 2012ZX09102301-018 ; 2012 BAK25B03-16 ; 31300 ; BMU20110263 ; 7132131 ; 7132123 ; Z121107002512010
资助机构National Natural Science Foundation of China (NSFC) ; "973" projects ; Ministry of Science and Technology of China ; Ministry of Education of China ; Beijing Natural Science Foundation ; Beijing Nova Program
引用统计
被引频次:8[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/56763
专题北京大学医药卫生分析中心
作者单位1.Peking Univ, Med Isotopes Res Ctr, Beijing 100191, Peoples R China
2.Peking Univ, Sch Basic Med Sci, Dept Radiat Med, Beijing 100191, Peoples R China
推荐引用方式
GB/T 7714
Dong, C.,Liu, Z.,Wang, F.. Peptide-based Radiopharmaceuticals for Targeted Tumor Therapy[J]. CURRENT MEDICINAL CHEMISTRY,2014,21(1):139-152.
APA Dong, C.,Liu, Z.,&Wang, F..(2014).Peptide-based Radiopharmaceuticals for Targeted Tumor Therapy.CURRENT MEDICINAL CHEMISTRY,21(1),139-152.
MLA Dong, C.,et al."Peptide-based Radiopharmaceuticals for Targeted Tumor Therapy".CURRENT MEDICINAL CHEMISTRY 21.1(2014):139-152.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Dong, C.]的文章
[Liu, Z.]的文章
[Wang, F.]的文章
百度学术
百度学术中相似的文章
[Dong, C.]的文章
[Liu, Z.]的文章
[Wang, F.]的文章
必应学术
必应学术中相似的文章
[Dong, C.]的文章
[Liu, Z.]的文章
[Wang, F.]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。